The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2022 | Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of GPRC5D and FcRH5-targeting therapies in multiple myeloma, highlighting agents such as talquetamab and cevostamab. Dr Lee comments on the efficacy of these agents observed in clinical trials, and further discusses their place in the myeloma treatment armamentarium. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
